Evidence map›Paper›PMID 32030522›Full record

ArticleJournal of neurology2020

Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.

Alejandra González-Duarte, John L Berk, Dianna Quan, Michelle L Mauermann, Hartmut H Schmidt, Michael Polydefkis, Márcia Waddington-Cruz, Mitsuharu Ueda, Isabel M Conceição, Arnt V Kristen and 9 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. [Neurological manifestations of ATTR amyloidosis].Innere Medizin (Heidelberg, Germany) · 2023
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Alejandra González-DuarteInstituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, CdMx, CP 01400, México City, Mexico. gonzalezduarte@aol.com.
John L BerkBoston Medical Center, Boston, MA, USA.
Dianna QuanUniversity of Colorado, Denver, CO, USA.
Michelle L MauermannMayo Clinic, Rochester, MN, USA.
Hartmut H SchmidtUniversity of Münster, Münster, Germany.
Michael PolydefkisJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Márcia Waddington-CruzHospital Universitário Clementino Fraga Filho-UFRJ, Rio de Janeiro, Brazil.
Mitsuharu UedaKumamoto University Hospital, Kumamoto, Japan.
Isabel M ConceiçãoCHULN, Hospital de Santa Maria and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Arnt V KristenUniversity of Heidelberg, Heidelberg, Germany.
Teresa CoelhoHospital de Santo António, Centro Hospitalar Universitário Do Porto, Porto, Portugal.
Cécile A CauquilAP-HP Université Paris Saclay, CHU Bicêtre, Le Kremlin Bicêtre, France.
Céline TardUniversité de Lille, Lille, France.
Madeline MerkelAlnylam Pharmaceuticals, Cambridge, MA, USA.
Emre AldincAlnylam Pharmaceuticals, Cambridge, MA, USA.
Jihong ChenAlnylam Pharmaceuticals, Cambridge, MA, USA.
Marianne T SweetserAlnylam Pharmaceuticals, Cambridge, MA, USA.
Jing Jing WangAlnylam Pharmaceuticals, Cambridge, MA, USA.
David AdamsAP-HP, Université Paris Saclay, CHU Bicêtre, Université Paris-Sud, INSERM 1195, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The original version of this article unfortunately contained a mistake.

Identifiers

PMID32030522
PMCPMC7035215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.